Cargando…

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis

BACKGROUND AND AIM: Given the paucity of evidence-based treatment recommendations, the most appropriate first-line regimen for adult Burkitt lymphoma is currently undefined. We aimed to identify the optimal treatment regimen containing rituximab for adult Burkitt lymphoma patients. METHODS: The PubM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Xiaoxuan, Liu, Yu, Liu, Ruyu, Liu, Jiaxin, Yan, Xiaojing, Qian, Liren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816660/ https://www.ncbi.nlm.nih.gov/pubmed/36620579 http://dx.doi.org/10.3389/fonc.2022.1063689

Ejemplares similares

Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study
por: Liu, Yu, et al.
Publicado: (2022)

Complete response to chemotherapy in Burkitt's Lymphoma of the Bladder: A case report
por: Shimizu, Ryutaro, et al.
Publicado: (2020)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma
por: Bagaloni, Irene, et al.
Publicado: (2021)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens
por: Oosten, L. E. M., et al.
Publicado: (2017)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
por: Chen, Meiting, et al.
Publicado: (2021)

Acute Intestinal Intussusception: Beware of Burkitt’s Lymphoma
por: Sahli, Hind, et al.
Publicado: (2022)

Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma
por: Xian, Rena R., et al.
Publicado: (2021)

Calcineurin-independent NFATc1 signaling is essential for survival of Burkitt lymphoma cells
por: Murti, Krisna, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Chen, Zegeng, et al.
Publicado: (2021)

Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab
por: Huang, Shuang, et al.
Publicado: (2021)

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study
por: Zhang, Yan, et al.
Publicado: (2021)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
por: Autore, Francesco, et al.
Publicado: (2020)

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
por: Rodrigo, J. A., et al.
Publicado: (2012)

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study
por: Ma, Jingjing, et al.
Publicado: (2022)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
por: Song, Bo, et al.
Publicado: (2023)

The Clinical Accuracy and Risk Stratification in End of Therapy (18)F-FDG PET/CT in Burkitt Lymphoma
por: Mo, Yi Wen, et al.
Publicado: (2021)

Burkitt's lymphoma in British adults: clinical features and response to chemotherapy.
por: Brearley, R. L., et al.
Publicado: (1977)

Rehabilitation for Ataxia Following Chemotherapy for Burkitt Lymphoma Involving the Rectum
por: Kim, Hyoung Seop, et al.
Publicado: (2012)

Xanthogranulomatous Appendicitis Mimicking Residual Burkitt's Lymphoma After Chemotherapy
por: Nam, Soomin, et al.
Publicado: (2016)

Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
por: Margiotta-Casaluci, Gloria, et al.
Publicado: (2023)

Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma.
por: Büyükpamukçu, M., et al.
Publicado: (1987)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Editorial: Advances in the treatment of primary central nervous system lymphoma
por: Qian, Liren, et al.
Publicado: (2023)

Burkitt Lymphoma in the Mouse
por: Kovalchuk, Alexander L., et al.
Publicado: (2000)

Burkitt Lymphoma of the Duodenum
por: Matsueda, Katsunori, et al.
Publicado: (2017)

Burkitt's lymphoma of the mandible
por: Kuo, Ying-Shiung, et al.
Publicado: (2017)

Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
por: Chen, Xinrui, et al.
Publicado: (2021)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma
por: Hu, Shaoxuan, et al.
Publicado: (2022)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Serum Metabolomics of Burkitt Lymphoma Mouse Models
por: Yang, Fengmin, et al.
Publicado: (2017)

Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study
por: Sun, Yu-Qian, et al.
Publicado: (2021)

Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol
por: Patekar, Mukesh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l06bg2f3fjo1v4kb4trcckr9v5